Key Finding
Acupuncture significantly improved clinical efficacy for chemotherapy-induced peripheral neuropathy in breast cancer patients by 22% overall, with strongest effects seen in taxane-induced and utidelone-induced cases.
Chemotherapy-induced peripheral neuropathy (CIPN) causes numbness, tingling, and pain in the hands and feet, affecting many breast cancer survivors undergoing treatment. This systematic review analyzed 10 randomized controlled trials involving 653 breast cancer patients to determine whether acupuncture could safely and effectively treat CIPN symptoms.
Researchers found that acupuncture significantly improved clinical outcomes compared to control groups, with a 22% improvement in overall effectiveness. The benefits were particularly strong for patients experiencing neuropathy from taxane chemotherapy drugs (commonly used in breast cancer treatment) and utidelone, another chemotherapy agent. Acupuncture also reduced pain intensity and improved scores on the FACT-NTX questionnaire, which measures neuropathy symptoms and their impact on daily life.
Interestingly, acupuncture did not show significant improvements in nerve conduction velocity measurements or general quality of life scores in this analysis. However, the treatment was found to be safe, with no significant difference in adverse reactions between acupuncture and control groups.
For breast cancer patients struggling with the painful and disabling effects of chemotherapy-induced nerve damage, these findings suggest acupuncture may offer meaningful symptom relief, particularly for taxane-related neuropathy. The treatment appears especially beneficial for reducing pain and improving functional outcomes related to neuropathy symptoms. Since CIPN can persist long after chemotherapy ends and has few effective conventional treatments, acupuncture represents a promising complementary approach. If you're considering acupuncture for chemotherapy-related neuropathy, seek treatment from a licensed acupuncturist experienced in oncology support care.
This systematic review and meta-analysis examined acupuncture efficacy for chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer patients. Ten RCTs with 653 participants were analyzed using RevMan 5.2 and Stata 16.0. Acupuncture demonstrated significant improvement in clinical efficacy versus controls (RD=0.22, 95% CI: 0.10-0.33; p<0.001). Subgroup analysis revealed stronger effects for taxane-induced CIPN (RD=0.26, p<0.001) and utidelone-induced CIPN (RD=0.33, p=0.004), while unspecified agents showed non-significant results. Acupuncture significantly reduced pain intensity (SMD=-0.65, p<0.001) and improved FACT-NTX scores (WMD=3.66, p=0.007). No significant differences emerged for peroneal nerve conduction velocity, quality of life scores, or adverse event incidence. Clinical takeaway: Acupuncture appears safe and effective for managing CIPN symptoms in breast cancer patients, particularly taxane- and utidelone-related cases, with notable benefits in pain reduction and neuropathy-specific functional outcomes.
Browse our directory of verified licensed practitioners near you.
Find a practitioner →📌 Acupuncture significantly improved total sleep time by approximately 30 minutes and sleep efficiency by 4.56% compared to control groups in breast cancer patients with systemic therapy-associated insomnia.
📌 Cognitive behavioral therapy and hypnosis have the strongest evidence for reducing vasomotor symptoms in breast cancer survivors, while acupuncture may provide modest benefit as an adjunctive nonpharmacological treatment option.
📌 Traditional acupuncture reduced hot flash and night sweat frequency by nearly 50% in breast cancer survivors taking tamoxifen, with sustained effects lasting at least 18 weeks after treatment ended.